Table 2.

Limited Range of Motion

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit+)
POST OP	Overall LROM (N=320)	157 (49.1%)	125 (39.1%)	31 (9.7%)	7 (2.2%)
	Vs Arm (N=320)					0.929	0.698
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67)	33 (49.3%)	28 (41.8%)	5 (7.5%)	1 (1.5%)
	AC (Doxorubicin and Cyclophosphamide) (N=99)	50 (50.5%)	36 (36.4%)	11 (11.1%)	2 (2.0%)
	Capecitabine (N=154)	74 (48.1%)	61 (39.6%)	15 (9.7%)	4 (2.6%)
	Vs Most Extensive Surgery (N=318)					0.034	0.480
	Breast Conserving Surgery (N=143)	80 (55.9%)	48 (33.6%)	14 (9.8%)	1 (0.7%)
	Full Mastectomy (N=175)	77 (44.0%)	75 (42.9%)	17 (9.7%)	6 (3.4%)
	Vs Axillary Dissection (N=320)					<0.001	0.466
	No (N=65)	48 (73.8%)	11 (16.9%)	6 (9.2%)	0 (0%)
	Yes (N=255)	109 (42.7%)	114 (44.7%)	25 (9.8%)	7 (2.7%)
	Vs RT (N=299)					0.668	0.938
	No (N=138)	66 (47.8%)	56 (40.6%)	14 (10.1%)	2 (1.4%)
	Yes (N=161)	81 (50.3%)	61 (37.9%)	16 (9.9%)	3 (1.9%)
	Vs Number of Nodes Examined (N=313)					<0.001	0.871
	0-3 (N=49)	35 (71.4%)	9 (18.4%)	5 (10.2%)	0 (0%)
	4-7 (N=53)	32 (60.4%)	15 (28.3%)	6 (11.3%)	0 (0%)
	8+ (N=211)	85 (40.3%)	99 (46.9%)	20 (9.5%)	7 (3.3%)
AT 12 MONTHS	Overall LROM (N=259)	179 (69.1%)	63 (24.3%)	14 (5.4%)	3 (1.2%)
	Vs Arm (N=259)					0.779	0.666
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	36 (66.7%)	15 (27.8%)	2 (3.7%)	1 (1.9%)
	AC (Doxorubicin and Cyclophosphamide) (N=82)	59 (72.0%)	19 (23.2%)	4 (4.9%)	0 (0%)
	Capecitabine (N=123)	84 (68.3%)	29 (23.6%)	8 (6.5%)	2 (1.6%)
	Vs Most Extensive Surgery (N=257)					0.339	0.417
	Breast Conserving Surgery (N=117)	85 (72.6%)	26 (22.2%)	5 (4.3%)	1 (0.9%)
	Full Mastectomy (N=140)	94 (67.1%)	35 (25.0%)	9 (6.4%)	2 (1.4%)
	Vs Axillary Dissection (N=259)					0.160	0.730
	No (N=56)	43 (76.8%)	9 (16.1%)	4 (7.1%)	0 (0%)
	Yes (N=203)	136 (67.0%)	54 (26.6%)	10 (4.9%)	3 (1.4%)
	Vs RT (N=245)					0.796	0.467
	No (N=109)	77 (70.6%)	26 (23.9%)	5 (4.6%)	1 (0.9%)
	Yes (N=136)	94 (69.1%)	32 (23.5%)	8 (5.9%)	2 (1.5%)
	Vs Number of Nodes Examined (N=254)					0.536	0.904
	0-3 (N=44)	33 (75.0%)	9 (20.5%)	2 (4.5%)	0 (0%)
	4-7 (N=39)	25 (64.1%)	11 (28.2%)	3 (7.7%)	0 (0%)
	8+ (N=171)	116 (67.8%)	43 (25.1%)	9 (5.3%)	3 (1.8%)
AT 24 MONTHS	Overall LROM (N=240)	190 (79.1%)	39 (16.3%)	8 (3.3%)	3 (1.3%)
	Vs Arm (N=240)					0.096	0.120
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	35 (71.4%)	10 (20.4%)	3 (6.1%)	1 (2.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=83)	63 (75.9%)	15 (18.1%)	4 (4.8%)	1 (1.2%)
	Capecitabine (N=108)	92 (85.2%)	14 (13.0%)	1 (0.9%)	1 (0.9%)
	Vs Most Extensive Surgery (N=238)					0.028	0.234
	Breast Conserving Surgery (N=108)	93 (86.1%)	12 (11.1%)	3 (2.8%)	0 (0%)
	Full Mastectomy (N=130)	97 (74.6%)	25 (19.2%)	5 (3.8%)	3 (2.3%)
	Vs Axillary Dissection (N=240)					0.748	0.862
	No (N=52)	42 (80.8%)	8 (15.4%)	2 (3.8%)	0 (0%)
	Yes (N=188)	148 (78.7%)	31 (16.5%)	6 (3.2%)	3 (1.6%)
	Vs RT (N=226)					0.691	0.292
	No (N=100)	78 (78.0%)	19 (19.0%)	3 (3.0%)	0 (0%)
	Yes (N=126)	101 (80.2%)	18 (14.3%)	5 (4.0%)	2 (1.6%)
	Vs Number of Nodes Examined (N=236)					0.465	0.832
	0-3 (N=41)	34 (82.9%)	6 (14.6%)	1 (2.4%)	0 (0%)
	4-7 (N=39)	33 (84.6%)	4 (10.3%)	0 (0%)	2 (5.1%)
	8+ (N=156)	120 (76.9%)	28 (18.0%)	7 (4.5%)	1 (0.6%)